COQ 1O Drug Co PATENTS
The bottom line is that the popular and widely prescribed cholesterol lowering drugs called "Statins" can block the synthesis of Coenzyme Q10 in the body which may lead to sub-optimal CoQ10 levels. Supplementation with Q-Gel CoQ-10 is a prudent approach when undergoing "statin" therapy.
But, don't just take our word for it. One of the world's premier Pharmaceutical Companies and the manufacturer of the 2nd largest selling statin drug has not one but two US Patents regarding the use of Coenzyme Q10 with HMG-COA Reductase Inhibitors (Statins). You can read the full contents of these patents for yourself on the official United States Patent and Trademark Office web site (www.uspto.gov/). It is interesting to note that both of these patents were issued many years ago (May and June of 1990) but that no use of the patented process of combining Coenzyme Q10 with HMG-COA Reductase Inhibitors (Statins) has yet been made or publicized.
The Patent numbers you will want to look up are: Patent Number: 4,933,165 Patent Number: 4,929,437
Below is a verbatim sample from Patent Number 4,933,165.
What is claimed is:
1. A pharmaceutical composition comprising a pharmaceutical carrier and an effective antihypercholesterolemic amount of an HMG-CoA reductase inhibitor and an amount of Coenzyme Q.sub.10 effective to counteract HMG-CoA reductase inhibitor-associated skeletal muscle myopathy.
2. A composition of claim 1 in which the HMG-CoA reductase inhibitor is selected from: lovastatin, simvastatin, pravastatin and sodium-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(methylethyl)-1H-Indole-2yl]- hept-6-enoate.
3. A method of counteracting HMG-CoA reductase inhibitor-associated skeletal muscle myopathy in a subject in need of such treatment which comprises the adjunct administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor and an effective amount of Coenzyme Q.sub.10 to counteract said myopathy.
4. A method of claim 3 in which the HMG-CoA reductase inhibitor is selected from the group consisting of: lovastatin, simvastatin, pravastatin and sodium-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(methylethyl)-1H-Indole-2yl]- hept-6-enoate."
To access these patents: Go to the official United States Patent and Trademark Office web site at (www.uspto.gov/). (We certainly hope you'll come back to epic4health.com later!). From the Patent offices home page "click" on the Patents button, then "click" on "Search Patents", then click on "Patent Number Search". Type in the patent number (4,933,165) in the "Query Box" and "click" on the search button. The Patent number and title will show up, then just click on the patent number and you will be able to read the full documentation, including who is assigned the patent. I've probably made this whole search process sound harder than it really is -- give it a try, you may be surprised by what you learn.
The products and claims made about specific products on our site have not been evaluated by any regulatory health authority and are not approved to diagnose, treat, cure or prevent disease. The information provided on our site is for informational purposes only. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any or stopping any medication, or if you have or suspect you might have a health problem.
“The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won't function normally if it doesn't churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer's disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make (see also Diabetes).
Scientists in the laboratory of C. Ronald Kahn, M.D., head of Joslin's Integrative Physiology and Metabolism research section, found that brain cholesterol synthesis, the only source of cholesterol for the brain, drops in several mouse models of diabetes. Their work was reported online in the journal Cell Metabolism on November 30. D”
Joanne Gjelsten